GlassScriptPhysician profile
Ari L Weitzner
NPI 1740296839
$2,071.08
in general payments reported to CMS, 2019-2025
18 companies · $385 in 2025
The $385 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $74.56 · 2021: $148 · 2022: $386 · 2023: $433 · 2024: $218 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,018 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,017.77 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $374.86 | 2022-2025 | Vuity, Lumigan, Alphagan P |
| Shire North American Group INC | $283.63 | 2019 | |
| Bausch & Lomb Americas INC. | $228.89 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Sun Pharmaceutical Industries INC. | $226.80 | 2022-2025 | Cequa |
| Oyster Point Pharma, INC. | $210.66 | 2022-2025 | Tyrvaya, Ryzumvi |
| Alcon Vision LLC | $153.79 | 2019-2025 | Eysuvis |
| Tarsus Pharmaceuticals, INC. | $112.17 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $103.26 | 2019-2022 | |
| Harrow Eye, LLC | $79.50 | 2025 | Vevye |
| Amgen INC. | $63.10 | 2024-2025 | Tepezza |
| Eyevance Pharmaceuticals LLC | $49.63 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $49.28 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $31.87 | 2019 | |
| Allergan, INC. | $24.95 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $24.74 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $20.39 | 2023 | Vabysmo |
| Horizon Therapeutics Plc | $18.56 | 2023 | Tepezza |
| Sight Sciences, INC. | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ari Weitzner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.